MOLN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.990

Open

3.990

VWAP

3.88

Vol

2.74K

Mkt Cap

147.03M

Low

3.710

Amount

10.64K

EV/EBITDA(TTM)

--

Total Shares

37.41M

EV

41.60M

EV/OCF(TTM)

--

P/S(TTM)

--

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Show More

Events Timeline

(ET)

2026-02-26

05:50:00

Molecular Partners Enters Agreement with Eckert & Ziegler for Radio-DARPin Development

2026-02-02 (ET)

2026-02-02

05:30:00

Molecular Partners Presents First Patient Imaging Data for MP0712 in South Africa

2026-01-11 (ET)

2026-01-11

16:00:00

Molecular Partners Updates 2026 Milestones and Development Plans

2025-12-11 (ET)

2025-12-11

07:20:00

Molecular Partners Forms Scientific Advisory Board for Radiopharmaceuticals

2025-12-07 (ET)

2025-12-07

13:40:00

Molecular Partners to Present MP0533 Trial Data at ASH Annual Meeting

2025-11-12 (ET)

2025-11-12

05:45:26

Molecular Partners unveils new data on MP0712

News

seekingalpha

03-12seekingalpha

Molecular Partners Reports FY 2025 Financial Results with Significant Losses

Yahoo Finance

03-12Yahoo Finance

Molecular Partners Initiates DLL3-Targeting Study for SCLC

Newsfilter

02-26Newsfilter

Molecular Partners to Release Full-Year 2025 Financial Report

Newsfilter

02-02Newsfilter

Significant Progress in MP0712 Clinical Development

Benzinga

Wall Street Analysts Adjust Ratings on Key Stocks

Globenewswire

01-11Globenewswire

Molecular Partners Initiates MP0712 Clinical Trial, First Patient Dosing Expected Q1 2026

2 Analyst Rating

Wall Street analysts forecast MOLN stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

10.00

High

12.00

Current: 0.000

Low

8.00

Averages

10.00

High

12.00

H.C. Wainwright

Buy

initiated

$13

AI Analysis

2026-01-27

Reason

H.C. Wainwright

Price Target

$13

AI Analysis

2026-01-27

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Molecular Partners with a Buy rating and $13 price target. The company is advancing a "diversified portfolio of agents" centered on the DARPin platform, the analyst tells investors in a research note. The firm says Molecular Partners is focused on targeted radiotherapy agents to address areas of serious unmet needs within oncology.

JPMorgan

Richard Vosser

Neutral

downgrade

$4

2025-12-08

Reason

JPMorgan

Richard Vosser

Price Target

$4

2025-12-08

downgrade

Neutral

Reason

JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $3.75 from $4 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MOLN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Molecular Partners AG (MOLN.O) is -3.11, compared to its 5-year average forward P/E of -2.24. For a more detailed relative valuation and DCF analysis to assess Molecular Partners AG's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.24

Current PE

-3.11

Overvalued PE

1.85

Undervalued PE

-6.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

2.12

Current EV/EBITDA

-0.75

Overvalued EV/EBITDA

32.99

Undervalued EV/EBITDA

-28.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

28.19

Current PS

0.00

Overvalued PS

71.91

Undervalued PS

-15.54

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best stock to short today

Intellectia · 38 candidates

Short Ratio: MoreThan30PctBeta: HighRiskWeek Price Change Pct: <= $-3.00

Ticker

Name

Market Cap$

Robinhood Markets Inc

95.24B

Coinbase Global Inc

61.19B

GDS Holdings Ltd

8.19B

Wingstop Inc

7.34B

MakeMyTrip Ltd

6.22B

Credit Acceptance Corp

4.87B

Whales Holding MOLN

BVF Partners L.P.

Suvretta Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Molecular Partners AG (MOLN) stock price today?

The current price of MOLN is 3.93 USD — it has decreased -3.04

What is Molecular Partners AG (MOLN)'s business?

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

What is the price predicton of MOLN Stock?

Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Molecular Partners AG (MOLN)'s revenue for the last quarter?

Molecular Partners AG revenue for the last quarter amounts to 0.00 USD, decreased

What is Molecular Partners AG (MOLN)'s earnings per share (EPS) for the last quarter?

Molecular Partners AG. EPS for the last quarter amounts to -0.34 USD, increased 13.33

How many employees does Molecular Partners AG (MOLN). have?

Molecular Partners AG (MOLN) has 149 emplpoyees as of April 01 2026.

What is Molecular Partners AG (MOLN) market cap?

Today MOLN has the market capitalization of 147.03M USD.